BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 12, 2008
View Archived Issues
Sanofi-aventis reports Q2 highlights
Read More
Santhera provides update on idebenone for the treatment of Friedreich's ataxia
Read More
KUR-212 follow-up results of phase IIa trial in patients with burns requiring mesh grafting
Read More
Enrollment in phase IIb clinical trial for I-vation TA (MK-0140) suspended
Read More
New delta opioid receptor antagonist with antitussive activity identified at Toray
Read More
Bioavailability similar with ritonavir tablet and capsule formulations
Read More
Study shows long-term efficacy of tipranavir-ritonavir treatment for children with AIDS
Read More
CASTLE data on atenovir/ritonavir, lopinavir/ritonavir analyzed by gender, race and renal effects
Read More
AstraZeneca: Q2 regulatory and development update
Read More
Aloe extract UP-780 upregulates adiponectin expression, reduces HbA1c
Read More
Novel antiviral, antibacterial agents disclosed in recent patents
Read More
New compounds for treatment of inflammation revealed in patent literature
Read More
Recent patents disclose new anticancer compounds
Read More
NeuroSearch reports positive results from TIPO-2 human metabolic study of tesofensine
Read More
FDA grants marketing approval to Gilead's Viread for chronic hepatitis B
Read More
FDA issues approvable letter for NDA for Kynapid in atrial fibrillation
Read More
Oncolytics completes dose escalation in REO 010 clinical trial of Reolysin and docetaxel
Read More
Enrollment completed in phase IIa study of brostallicin in soft tissue carcinoma
Read More
Fresenius Kabi completes acquisition of Dabur Pharma
Read More
Preclinical data on memogain, a galantamine prodrug, reported by Galantos
Read More
ErbB3 antagonist MM-121 begins phase I trial
Read More
Phase III study of Trizytek meets primary endpoint
Read More